Fig. 6

COX-2 inhibition downregulated the TGF-β-TGFBR1-β-catenin signaling pathway in vivo. a Comparison of the key protein levels of the TGF-β-TGFBR1-β-catenin signaling pathway in liver tissues between cirrhotic patients and healthy controls (WB). b Comparison of the key protein levels of the TGF-β-TGFBR1-β-catenin signaling pathway and COX-2 in the livers of the WT-NS, WT-TAA, and KO-TAA groups (WB). c The effects of panknockout of COX-2 on the expression of active β-catenin and Cyclin D1 in liver sections (IF). d The effects of pharmaceutical inhibition of COX-2 by imrecoxib on the expression of active β-catenin and Cyclin D1 in liver sections (IF). e The effects of hepatocyte-specific knockout of COX-2 on the expression of active β-catenin and Cyclin D1 in liver sections (IF). Images were cropped and scaled for illustration purposes from original Western blot images provided in supplementary files. Scale bars 50μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant (one-way ANOVA, n = 3/group)